TG Therapeutics Stock Climbs 15% On A 6-Day Winning Streak
Shares of TG Therapeutics (TGTX) have closed higher in each of the last 6 sessions, a cumulative gain of 15.1%. That added about $1.1 billion to the company’s market value, which now stands at about $8.7 billion. The stock closed at $61.18 on Friday, October 30, its highest close of the past year.
TGTX Versus The S&P 500
Returns for TGTX and the S&P 500 over the streak and the periods around it, all ending Friday, October 30 and including dividends:
| Return Period | TGTX | S&P 500 |
|---|---|---|
| 1 Day | 5.3% | -1.8% |
| 6 Days (Current Streak) | 15.1% | -1.1% |
| 1 Month (21 Trading Days) | 14.1% | -1.1% |
| 3 Months (63 Trading Days) | 32.5% | 0.0% |
| Year To Date | 105.2% | 11.8% |
| 1 Year (252 Trading Days) | 81.1% | 11.3% |
Is This Move About TG Therapeutics Or The Market?
The market explains little of this: the S&P 500 lost 1.1% over the same 6 sessions, including dividends, against TG Therapeutics’ +15.1%. Over the past three months the stock is up 32.5%, a window that includes the streak; over the other 57 sessions of that window it was up 15.1%.
Is The Business Keeping Up With The Stock?
On the fundamentals, revenue grew 76.1% over the last twelve months, against a median of 8.0% for S&P 500 Health Care stocks; its operating margin is 17.1%, versus a median of 16.6%; and the stock trades at 19.6 times trailing earnings against a median of 30.8. On these numbers the run has substance behind it: revenue growth above the median, margins above the median and a multiple below the median.
A climb like this is worth respecting, and worth testing. Our Guidance Momentum screen tracks the stocks whose companies just raised their own forward numbers.
For anyone who would rather back the theme than one company, a biotech ETF like XBI holds the whole group, not just this stock. It is still a concentrated bet on one theme, which is the gap the portfolio below is built to close.
Momentum Is A Tailwind, Not A Plan
Riding a stock that rises every day feels effortless, and that is precisely the danger: the same momentum that built this run can reverse without notice, and one name’s reversal should never be able to reset your whole year.
That is what the Trefis High Quality (HQ) Portfolio is for: about 30 quality businesses screened for the fundamentals that survive momentum’s mood swings, held with rules. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Watch the runs; own the resilience.